Caplin Point Laboratories surges as its arm signs agreement with Xellia Pharmaceuticals

07 Jul 2020 Evaluate
Caplin Point Laboratories is currently trading at Rs. 344.00, up by 3.35 points or 0.98% from its previous closing of Rs. 340.65 on the BSE.

The scrip opened at Rs. 340.00 and has touched a high and low of Rs. 352.30 and Rs. 340.00 respectively. So far 9474 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 456.00 on 14-Aug-2019 and a 52 week low of Rs. 180.00 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 355.95 and Rs. 307.00 respectively. The current market cap of the company is Rs. 2610.05 crore.

The promoters holding in the company stood at 69.03%, while Institutions and Non-Institutions held 4.47% and 26.50% respectively.

Caplin Point Laboratories’ wholly owned subsidiary company -- Caplin Steriles has entered into a private label distribution agreement with Xellia Pharmaceuticals for five generic injectable ANDAs in the US. The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1740.80 -35.95 (-2.02%)
21-Jan-2026 15:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1611.90
Dr. Reddys Lab 1158.20
Cipla 1369.40
Zydus Lifesciences 875.55
Lupin 2140.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×